125 related articles for article (PubMed ID: 12803174)
1. Cancer gene therapy: lessons learned from experiences with chemotherapy.
Morris JC
Mol Ther; 2003 Jun; 7(6):717-9. PubMed ID: 12803174
[No Abstract] [Full Text] [Related]
2. Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model.
Galaup A; Opolon P; Bouquet C; Li H; Opolon D; Bissery MC; Tursz T; Perricaudet M; Griscelli F
Mol Ther; 2003 Jun; 7(6):731-40. PubMed ID: 12788646
[TBL] [Abstract][Full Text] [Related]
3. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer.
Patel AR; Sandler HM; Pienta KJ
Clin Genitourin Cancer; 2005 Dec; 4(3):212-4. PubMed ID: 16425991
[No Abstract] [Full Text] [Related]
4. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
[TBL] [Abstract][Full Text] [Related]
5. Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents.
Li Y; Okegawa T; Lombardi DP; Frenkel EP; Hsieh JT
J Urol; 2002 Jan; 167(1):339-46. PubMed ID: 11743353
[TBL] [Abstract][Full Text] [Related]
6. Highlights from the XII European Cancer Conference Copenhagen, Denmark.
Tyagi P; Price N; Reddy K; Klem J
Clin Prostate Cancer; 2003 Dec; 2(3):137-41. PubMed ID: 15040855
[No Abstract] [Full Text] [Related]
7. E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases.
Zhao P; Luo R; Wu J; Xie F; Li H; Xiao X; Fu L; Zhu X; Liu R; Zhu Y; Liang Z; Huang W
J Cell Mol Med; 2010 Jan; 14(1-2):381-91. PubMed ID: 26065034
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model.
Raikwar SP; Temm CJ; Raikwar NS; Kao C; Molitoris BA; Gardner TA
Mol Ther; 2005 Dec; 12(6):1091-100. PubMed ID: 16169279
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in androgen-independent prostate cancer: an update.
Khan MA; Carducci MA; Partin AW
BJU Int; 2004 Dec; 94(9):1209-10. PubMed ID: 15610087
[No Abstract] [Full Text] [Related]
10. New treatment hope for prostate cancer.
Moyer P
Lancet Oncol; 2004 Jan; 5(1):5. PubMed ID: 14723225
[No Abstract] [Full Text] [Related]
11. Clinical features of docetaxel chemotherapy-related lymphedema.
Park SI; Jeon WH; Jeung HJ; Kim GC; Kim DK; Sim YJ
Lymphat Res Biol; 2014 Sep; 12(3):197-202. PubMed ID: 25144149
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel treatment in castration-resistant prostate cancer: the triad gene-drug-disease.
Faucz FR
J Clin Endocrinol Metab; 2011 Feb; 96(2):351-3. PubMed ID: 21296995
[No Abstract] [Full Text] [Related]
13. [Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].
Batman E; de Wit R
Ned Tijdschr Geneeskd; 2005 Oct; 149(44):2442-5. PubMed ID: 16285357
[TBL] [Abstract][Full Text] [Related]
14. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo.
Nishizaki M; Meyn RE; Levy LB; Atkinson EN; White RA; Roth JA; Ji L
Clin Cancer Res; 2001 Sep; 7(9):2887-97. PubMed ID: 11555607
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.
Yoo GH; Piechocki MP; Oliver J; Lonardo F; Zumstein L; Lin HS; Kim H; Shibuya TY; Shehadeh N; Ensley JF
Laryngoscope; 2004 Nov; 114(11):1871-9. PubMed ID: 15510008
[TBL] [Abstract][Full Text] [Related]
16. Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
Harrington JA; Jones RJ
Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937
[TBL] [Abstract][Full Text] [Related]
17. [Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma].
Miller K; Becker K; Finke F; Geiges G; Göckel-Beining B; Hossfeld DK; Miller K; Osieka R; Rüssel C; Tesch H; Weissbach L; Wirth M; Wolff JM
Aktuelle Urol; 2006 May; 37(3):201-4. PubMed ID: 16733822
[TBL] [Abstract][Full Text] [Related]
18. [Docetaxel and squamous cell carcinoma of the head and neck].
Calais G
Bull Cancer; 2004 Feb; 91(2):167-71. PubMed ID: 15047456
[TBL] [Abstract][Full Text] [Related]
19. Modeling antiangiogenesis gene therapy.
Tsai JH; Lee WM
Cancer Biol Ther; 2002; 1(5):554-5. PubMed ID: 12496488
[No Abstract] [Full Text] [Related]
20. [Chemotherapy of prostate cancer: potential role of docetaxel].
Bracarda S
Tumori; 2001; 87(6):A12-4. PubMed ID: 11995697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
